← Daily Brief
The Bell BriefFrom Dr. Jennifer Bell, DDS
MEDIUMClinicalTier 1

TGF-β1 Directs TFAM-Mediated Mitochondrial Reprogramming in Oral Submucous Fibrosis

SourceJournal of Dental Research (JDR)Tier 1Peer-Reviewed Research

By K.M. Desai, N.A. Tadkalkar, M. Amin, R. Kumar, S.U. Rahman, S. Ponnusamy, P. Angadi, W. Liu, R.V Dayani, A.D. Kale, J. Slone, D. Chandra, P.R. Arany

Originally at journals.sagepub.com

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

This basic-science finding links arecoline and TGF-β1 to mitochondrial reprogramming in oral submucous fibrosis (OSMF), a premalignant condition that can progress to oral squamous-cell carcinoma—knowledge that oral surgeons, periodontists, and any practice treating betel-nut users need to anticipate future diagnostic or therapeutic targets.

Key points

  • Journal of Dental Research (July 2026) shows TGF-β1 up-regulates TFAM, driving mitochondrial biogenesis in OSMF fibroblasts and altering ATP production and redox balance.
  • Arecoline, the primary alkaloid in areca nut, synergizes with TGF-β1 to amplify the mitochondrial phenotype, providing a mechanistic basis for the high malignant transformation rate (~7–13 %) seen in chronic OSMF.
  • Future assays targeting TFAM or mitochondrial metabolites could yield chair-side adjuncts for risk-stratifying OSMF lesions beyond current histopathology.
  • DSO and specialty practices serving South-Asian populations should track emerging biopsy or saliva-based mitochondrial biomarkers that may soon supplement visual screening.

Who should care

SpecialistOwner

Read the original on Journal of Dental Research (JDR)

Full reporting and any paywall content live on journals.sagepub.com. We summarize and score; we do not republish.

Open original

Related